ATRA Inhibits the Proliferation of DU145 Prostate Cancer Cells through Reducing the Methylation Level of HOXB13 Gene

Zhiwei Liu1, Guoling Ren2, Chenyan Shangguan1, Lijing Guo1, Zhixiong Dong3, Yueyang Li1, Weina Zhang4, Li Zhao4, Pingfu Hou4, Yu Zhang1, Xiuli Wang1, Jun Lu4*, Baiqu Huang1*

1 The Institute of Genetics and Cytology, Northeast Normal University, Changchun, China, 2 College of Life Sciences, Daqing Normal University, Daqing, Heilongjiang, China, 3 The College of Life Science, Tianjin Normal University, Tianjin, China, 4 The Key Laboratory of Molecular Epigenetics of Ministry of Education, Northeast Normal University, Changchun, China

Abstract

All-trans retinoic acid (ATRA) has been widely investigated for treatments of many cancers including prostate cancer. HOXB13, silenced in androgen receptor-negative (AR-) prostate cancer cells, plays a role in AR- prostate cancer cell growth arrest. In this study we intended to elucidate the mechanisms that are involved in the proliferation inhibition of AR- prostate cancer cells triggered by ATRA. We discovered that ATRA was able to induce the growth arrest and to increase HOXB13 expression in AR- prostate cancer cells. Both EZH2 and DNMT3b participated in the repression of HOXB13 expression through an epigenetic mechanism involving DNA and histone methylation modifications. Specifically, EZH2 recruited DNMT3b to HOXB13 promoter to form a repression complex. Moreover, ATRA could upregulate HOXB13 through decreasing EZH2 and DNMT3b expressions and reducing their interactions with the HOXB13 promoter. Concurrently, the methylation level of the HOXB13 promoter was reduced upon the treatment of ATRA. Results from this study implicated a novel effect of ATRA in inhibition of the growth of AR- resistant human prostate cancer cells through alteration of HOXB13 expression as a result of epigenetic modifications.

Citation: Liu Z, Ren G, Shangguan C, Guo L, Dong Z, et al. (2012) ATRA Inhibits the Proliferation of DU145 Prostate Cancer Cells through Reducing the Methylation Level of HOXB13 Gene. PLoS ONE 7(7): e40943. doi:10.1371/journal.pone.0040943

Editor: Fazlul H. Sarkar, Wayne State University School of Medicine, United States of America

Received April 20, 2012; Accepted June 15, 2012; Published July 13, 2012

Copyright: © 2012 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from The National Natural Science Foundation of China (30971613, 31071149, 91019011, 30800557), and The Fundamental Research Funds for the Central Universities (09ZDQG01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: huangbq705@nenu.edu.cn (BQH); ycsuo@nenu.edu.cn (JL)

† These authors contributed equally to this work.

Introduction

Prostate cancer is the most common malignancy in men in Europe, North America and in a number of African countries [1,2]. The incidence of prostate cancer has increased following the aging of population worldwide [3]. At present, conventional therapies such as surgery and hormone treatment frequently fail to achieve the satisfactory effect. Moreover, cancer cells may acquire therapies such as surgery and hormone treatment frequently fail to achieve the satisfactory effect. Moreover, cancer cells may acquire resistance through epigenetic modifications. Specifically, HOXB13 is silenced in androgen receptor-negative (AR-) prostate cancer cells, plays a role in AR- prostate cancer cell growth arrest. In this study we intended to elucidate the mechanisms that are involved in the proliferation inhibition of AR- prostate cancer cells triggered by ATRA. We discovered that ATRA was able to induce the growth arrest and to increase HOXB13 expression in AR- prostate cancer cells. Both EZH2 and DNMT3b participated in the repression of HOXB13 expression through an epigenetic mechanism involving DNA and histone methylation modifications. Specifically, EZH2 recruited DNMT3b to HOXB13 promoter to form a repression complex. Moreover, ATRA could upregulate HOXB13 through decreasing EZH2 and DNMT3b expressions and reducing their interactions with the HOXB13 promoter. Concurrently, the methylation level of the HOXB13 promoter was reduced upon the treatment of ATRA. Results from this study implicated a novel effect of ATRA in inhibition of the growth of AR- resistant human prostate cancer cells through alteration of HOXB13 expression as a result of epigenetic modifications.

All-trans retinoic acid (ATRA), the vitamin A metabolite, plays an essential role in the development by regulating cellular processes such as proliferation, differentiation and migration [12]. ATRA implements its effect by binding specific nuclear receptor superfamily, the retinoic acid receptors (RARs). The RARs form a heterodimer with the retinoid X-receptor [13]. Early studies revealed that treatment of leukemia cells with ATRA resulted in the apoptosis, presumably secondary to the
differential growth process [14,15]. Since ATRA can rectify aberrant cell growth and induce apoptosis, it has been widely investigated in preclinical and clinical trials for the treatment of many cancer types, including early gastric cancer and prostate cancer [16,17]. In AR− and drug resistant DU145 prostate cancer cells, ATRA was demonstrated to increase the sensitivity of cells to anticancer agent docetaxel; however the mechanisms how ATRA alone induces cell growth arrest remain unclear [18].

PcG proteins are global repressors of gene expression through the formation of polycomb repressive complex (PRC), such as PRC1 and PRC2 [19]. Several PcG proteins have been implicated in oncogenic activities [20]. There have been indications that PcG repressor activity is increased during prostate cancer progression [21]. Moreover, some PcG gene products were also found to be required for the stable silencing of Hox genes throughout Drosophila development [22]. Enhancer of Zeste Homologue 2 (EZH2), the catalytic subunit of PRC2, possesses a histone methyltransferase activity for histone 3 lysine 27 trimethylation (H3K27me3), which establishes a strong repressive signal for gene expression [19]. It was shown that ectopic overexpression of EZH2 not only stimulated cell proliferation, but also promoted anchorage-independent growth and cell invasion in vitro [20]. In contrast, depletion of EZH2 by small interfering RNAs (siRNAs) inhibited cell proliferation and induced apoptosis in prostate, breast, and colon cancer cells [23,24,25].

Methylation of DNA is a major epigenetic modification that influences gene transcription. DNA methylation in mammalian cells is established and maintained by DNMTs. Methylation is initiated by highly homologous DNMT3a and DNMT3b, and heritably propagated by DNMT1 [26]. Among these three enzymes, upregulation of DNMT3b is a characteristic of many cancer cells, and DNMT3b may play a causal role in tumorigenesis [27]. Studies in a mouse model showed that overexpression of DNMT3b, but not DNMT3a, promoted colon tumorigenesis in ApcMin/+ mice [28]. A previous study demonstrated that expression of HOXB13 was controlled in a methylation-dependent manner and its methylation was correlated positively with tumor grade and microvessel invasion [29]. In colon cancer cells, HOXB13, as a target of DNMT3b, was methylated at an upstream CpG island, and functioned as a tumor suppressor in primary colorectal tumors [26].

Since DNMT3b does not have DNA-binding domains, it needs transcription co-factors for interacting with specific gene sequences [30]. It has been known that many members of PcG, such as EZH2, possess the binding domains for HOX promoters, and they suppress HOX expression through histone methylation [31]. Significantly, EZH2 has been implicated to play a key role in mediating both histone methylation and DNA methylation of HOXB13 gene in some cancer cells [21,32]. Also, we previously reported that YY1 and the histone deacetylase 4 (HDAC4) affected prostate cancer cell growth by repressing HOXB13 transcription through histone modification [11]. These available data intrigued us to speculate that EZH2 might be able to recruit DNMT3b to HOXB13 promoter to repress its expression through particular epigenetic modifications.

The purpose of this study was to elucidate the mechanisms that are involved in the inhibition of proliferation in AR− prostate cancer cells triggered by ATRA. Our results revealed that ATRA inhibited the growth of DU145 prostate cancer cells through upregulating HOXB13 expression by reducing its methylation level. This was achieved by ATRA to impair the action of EZH2 and DNMT3b, which are responsible for the methylation of HOXB13 promoter. Data unraveled from this study may provide useful clues to the development of new therapeutic strategies for AR− prostate cancer that involve the use of ATRA and epigenetic modifiers.

Results

HOXB13 was Involved in ATRA-induced DU145 Cell Growth Arrest

ATRA was reported to be able to induce cell growth arrest, but the mechanism is not fully clear. Overexpression of HOXB13 in AR− prostate cancer cells can also result in significant inhibition of cell growth. To clarify whether HOXB13 plays a role in ATRA-induced growth arrest in prostate cancer cells, we first tested the relative cell survival rate upon the treatment of ATRA. DU145 cells were exposed to increasing concentrations of ATRA (from 20 to 120 µM) for 24, 48 and 72 h. As evidenced in Fig. 1A and 1B, ATRA indeed induced cell growth arrest in DU145 cells in a dose-dependent manner. High cytotoxicity was observed at 72 h. Meanwhile, both HOXB13 mRNA and protein levels were elevated in DU145 cells upon ATRA treatment (Fig. 1C). We further verified the effect of ATRA in another AR− prostate cancer cell line PC-3, and we observed the similar dose-dependent effect of ATRA on cell growth arrest, as revealed by MTT assays (Fig. S1). Meanwhile, both HOXB13 mRNA and protein levels were also elevated upon ATRA treatment (Fig. S2).

Next, to test the role of HOXB13 in ATRA-mediated DU145 cell growth arrest, we transiently transfected the HOXB13 siRNA plasmid into DU145 cells treated with ATRA. The construction and interfering efficiency of the HOXB13 siRNA were described in our previous report [11]. We found that knockdown of HOXB13 by siRNA apparently reversed the cell growth arrest induced by ATRA (Fig. 1D). This implicated that the ATRA-induced DU145 cell growth arrest was associated, at least in part, with the expression of HOXB13.

DNMT3b Participated in HOXB13 Transcriptional Repression

HOXB13 gene is silenced in AR− prostate cancer cells and overexpression of HOXB13 in AR− prostate cancer cells resulted in significant inhibition of cell growth [10]. We then investigated the molecular events that are involved in HOXB13 gene silencing in AR− prostate cancer cells. The promoter of HOXB13 has been frequently reported to be hypermethylated in various cancers [33]. To clarify whether silencing of HOXB13 gene is mediated by DNA hypermethylation in AR− prostate cancer cells, we assessed the methylation status of the HOXB13 promoter by using the bisulfite-sequencing PCR (BSP), and we found that the HOXB13 promoter was more intensively methylated in DU145 cells in comparison with that in the lowly malignant LnCaP cells (Fig. 2A, B).

Since the DNA methyltransferase DNMT3b plays an important role in methylation of cancer-related genes, and HOXB13 was reported to be a target gene of DNMT3b in primary colorectal tumors [26,27], we speculated that DNMT3b may also be involved in HOXB13 transcriptional repression in DU145 cells. To verify this assumption, we knocked down the DNMT3b expression with a specific siRNA, and we found that the HOXB13 expression was apparently increased in DU145 cells and the interfering efficiency of the DNMT3b siRNA was shown (Fig. 2C). The results from BSP assays showed that the methylation level of HOXB13 promoter in DU145 was reduced after knockdown of the endogenous DNMT3b (Fig. 2D, lower), compared with the control cells (Fig. 2D upper). These results suggested that the DNA methylation modification mediated by DNMT3b was responsible for the silencing of HOXB13 in DU145 cells.
The PcG Proteins EZH2 and BMI1 Participated in HOXB13 Transcriptional Repression

Next, we intended to determine the transcription factor(s) that may participate in regulation of HOXB13 gene. The PcG proteins have been reported to play a role in progression of prostate and breast cancers, as well as in silencing of HOXs [3,21,34,35]. We first determined that expressions of PcG proteins EZH2 and BMI1 were significantly higher in highly malignant DU145 cells than in lowly malignant LNCaP cells, and their expressions were negatively correlated to HOXB13 expression, as revealed by RT-PCR and western blotting (Fig. 3A, B).

To further clarify whether EZH2 and BMI1 participated in HOXB13 transcriptional repression in DU145 prostate cancer cells, we constructed EZH2 siRNA and BMI1 siRNA plasmids and transfected them into DU145 cells, respectively. We detected that both HOXB13 mRNA (Fig. 3C, E) and protein (Fig. 3D, F) levels were upregulated when EZH2 and BMI1 were knocked down. The inhibitory efficiencies of these siRNA plasmids on endogenous EZH2 and BMI1 at mRNA and protein levels were shown (Fig.3C, D and E, F). These results indicated that EZH2 and BMI1 may repress HOXB13 expression by mediating the histone methylation modification.

DNMT3b was Recruited to HOXB13 Promoter by EZH2

As co-repressors of transcription, DNMTs do not possess canonical DNA-binding domains and they are usually recruited to specific chromatin regions by transcription factors [26,30]. Significantly, EZH2 has been reported to play a key role in mediating both histone methylation and DNA methylation of HOXB13 gene in some cancer cells [21,32]. We then wanted to determine whether EZH2 recruits DNMT3b to HOXB13 promoter. We performed ChIP assays to detect changes in association of EZH2 at the three defined regions (P1–P3) of the HOXB13 promoter upon the knockdown of endogenous EZH2. The far upstream P4 region was chosen as a negative control (Fig. 4A).

The ChIP results demonstrated that the abundance of EZH2 at P1–P3 of HOXB13 promoter was reduced when endogenous EZH2 was suppressed by EZH2 siRNA in DU145 cells. Concurrently, the H3K27me3 level associated with EZH2 function at P1–P3 was apparently reduced (Fig. 4B).

Moreover, CoIP assays with DU145 cell extracts revealed that complexes were immunoprecipitated by anti-DNMT3b or anti-EZH2 antibodies, and could be detected in immunoblotting by anti-EZH2 or anti-DNMT3b antibodies, respectively (Fig. 4C), suggesting that DNMT3b and EZH2 were present in the same complex. Our ChIP data in Fig. 4D further indicated that the abundance of DNMT3b at the three promoter regions (P1–P3) was reduced upon the knockdown of endogenous EZH2. Thus, these results provided evidence that DNMT3b was recruited to HOXB13 promoter by EZH2.

ATRA Impaired EZH2 and DNMT3b Expression and Weakened their Interactions with HOXB13 Promoter

We have demonstrated above that HOXB13 was downregulated by EZH2 and DNMT3b, and ATRA treatment resulted in a raise in HOXB13 expression in DU145 cells. To verify our assumption that ATRA may facilitate HOXB13 expression through impairing the negative regulatory effects of EZH2 and DNMT3b on HOXB13, we examined the EZH2 and DNMT3b expression in DU145 cells treated with 80 μM ATRA, and 5-aza-2'-deoxycytidine (5-aza-dc) was used as the demethylation control. The results showed that expressions of both EZH2 and DNMT3b were downregulated upon ATRA treatment at both mRNA and protein levels (Fig. 5A, B). Similar results were obtained from a parallel study using another AR malignant prostate cancer cell line PC-3 (Fig. S2).

Our ChIP assays further demonstrated that the bindings of endogenous EZH2 and DNMT3b on HOXB13 promoter was reduced after ATRA treatment, and meanwhile the H3K27me3 levels at P1–P3 regions were apparently decreased (Fig. 5C).
Moreover, BSP assays revealed that treatment with ATRA resulted in the reduction of methylation level of CpG islands on HOXB13 promoter in contrast to that of untreated DU145 cells (Fig. 5D). Apparently, EZH2 recruited DNMT3b to HOXB13 promoter and triggered the gene silence by inducing the H3K27me3 and by increasing the methylation of CpG islands. Meanwhile, both the DNA methylation and H3K27me3 of HOXB13 promoter could be reduced by ATRA.

**Discussion**

ATRA plays an essential role in the development by regulating various cellular processes and it has been widely investigated in preclinical and clinical trials as an agent for the treatment of many cancer types, including early gastric cancer and prostate cancer [16,17]. Also, HOXB13 was shown to play a part in growth arrest in AR- prostate [10], colorectal cancer [26] and renal cell carcinoma [29]. In line with these previous data, results from this study demonstrated that ATRA was able to induce growth arrest of two AR- prostate cancer cells DU145 and PC-3 in a dose-dependent manner (Fig. 1A and Fig. S1), and this effect was partially achieved through promoting HOXB13 mRNA and protein production (Fig. 1C and S2, S3). Contrarily, a recent report described that knockdown of endogenous HOXB13 by RNA interference in human ovarian cancer cell lines was associated with reduced cell proliferation [36]. These contradictory descriptions may be the results from the apparent difference between ovary and other organs, since HOXB13 is unexpressed in normal ovary [36], whereas it is expressed at a high level in normal prostate and kidney [5,29]. Nevertheless, data presented in this report provide evidence that ATRA treatment inhibited the growth of DU145 prostate cancer cells, through a mechanism that involved the upregulation of HOXB13 by reducing the methylation level at gene’s promoter.

DNA methylation is catalyzed and maintained by DNMTs. Certain DNMTs, expressed at relatively low levels in somatic cells, are frequently upregulated in cancer cells. Gain-of-function studies showed that DNMT3b but not DNMT3a promoted colon tumorigenesis in APC^{Min/+} mice by inducing de novo methylation of multiple genes harboring CpG islands [26]. There was also indication that depletion of DNMT3b resulted in increased apoptosis rate and reduced migration of PC-3 prostate cancer cells [37]. In this study, we showed that HOXB13 expression was silenced in DU145 (Fig. S4), and BSP assays revealed that its silence may be related to the hypermethylation of the gene promoter (Fig. 2A). It was reported that HOXB13 gene was a target of DNMT3b in colon cancer cells [26]. It therefore becomes important to understand the function of DNMT3b in silencing of HOXB13 gene in DU145 prostate cancer cells. Our results demonstrated that DNMT3b could regulate HOXB13 transcription through altering the DNA methylation modification at gene’s promoter, although knockdown of DNMT3b did not reduce the methylation of CpG in HOXB13 promoter as expected (Fig. 2C, D). Apparently, other mechanisms may exist underlying the DNMT3b-mediated HOXB13 repression.
In particular, normal and aberrant methylation patterns may be mediated by chromatin proteins guiding DNA methyltransferases to their target genes [38]. Most recently, the PcG protein EZH2 was reported to recruit DNA methyltransferases, especially DNMT1 and DNMT3b, to implement the silencing of the MYT1 and WNT1 loci through DNA methylation [21,32]. Overexpression of EZH2 usually occurs in a diverse of malignancies, including prostate, breast and liver cancers, especially in advanced cases [39]. Varambally et al [40] concluded that deregulated expression of EZH2 may be a cause of prostate cancer progression, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression. Our results suggested that PcGs participated in prostate cancer development. We showed that the expression of EZH2 and BMI1 was much higher in DU145 cells than in LNCap cells (Fig. 3A, B). More interestingly, we found that PcGs suppressed HOXB13 expression in DU145 cells. RT-PCR and western blotting assays showed that HOXB13 expression was upregulated when EZH2 and BMI1 were knocked down (Fig. 3C, D, E and F). Furthermore, our ChIP assays revealed that EZH2 was able to directly bind onto the HOXB13 promoter (Fig. 4B), and this may be a silencing mechanism of HOXB13 in the DU145 malignant prostate cancer cells.

It has been proposed that EZH2 represses the transcription of target genes mainly through two different mechanisms. The first involves the binding of EZH2 to the target gene’s promoter to induce the H3K27me3 modification, thereby decreasing the promoter activity [39,41]. The second mechanism suggests that EZH2 recruits a co-repressor or complex, such as DNMT1 and DNMT3b, to the promoter and this co-repressor either negatively affects other factors that are present, or alters the local chromatin structure to facilitate repression [30,35]. Apparently, results from this study are in general agreement with both of the two models. Specifically, our data demonstrated that EZH2 was able to directly bind to the HOXB13 promoter to induce the H3K27me3 modification (Fig. 4B). Meanwhile, our data also suggested that EZH2 may recruit DNMT3b to HOXB13 promoter to affect the promoter methylation status and hence repress the gene transcription (Fig. 4C, D). These results provide further evidence for a crosstalk between the two distinct epigenetic mechanisms in gene silence.
ATRA is usually used in combination with other drugs, such as docetaxel, TSA and zoledronic acid in prostate cancer therapy [18,42,43], but the molecular mechanism of ATRA action is unclear. The fact that EZH2 recruits DNMT3b to the HOXB13 promoter to repress the gene expression, and that treatment with ATRA results in the upregulation of the HOXB13 expression, intrigued us to propose a hypothesis that ATRA could upregulate HOXB13 through decreasing the methylation level of the gene induced by EZH2 and DNMT3b. Results from this study validated that the expressions of EZH2 and DNMT3b were decreased after ATRA treatment in both DU145 and PC-3 cell lines (Fig.5A, B and Fig. S2, S3). Also, the bindings of EZH2 and DNMT3b onto the HOXB13 promoter and the H3K27me3 level whereby were reduced in DU145 cells treated with ATRA (Fig. 5C). Interestingly, BSA assays revealed that the DNA methylation level of the HOXB13 promoter was also decreased in DU145 cells upon ATRA treatment (Fig. 5D).

There are threeRAR genes, i.e., RARα, β and γ in cells, and they are all required for ATRA function. Since RARβ is silenced in DU145 cells, the sensitivity of the DU145 cells to ATRA is lower than that of LNCap cells [44]. Meanwhile, we also examined the effect of ATRA in 293 and 293T cells, the two normal human embryonic kidney cell lines. As expected, the sensitivity of these cells to ATRA was higher than that in DU145 cells (Fig.S5A). Noticeably, treatment of AR prostate cancer cells with ATRA did not change the expressions of HOXB13, EZH2 and DNMT3b at mRNA level (Fig. S5B), implicating a different mechanism of ATRA action in this particular cell background. Presumably, the epigenetic modifications mediated by ATRA described in this report may probably be restricted to certain cancer cell types like AR prostate cancer cells, since there have been no reports of ATRA-mediated epigenetic modifications in normal cells to date. Likewise, the more malignant and drug resistant PC-3 cells exhibited an even higher sensibility to ATRA than DU145 cells (Fig. S1).

A previous report unraveled that reduced DNMT3b expression resulted in hypomethylation of retinoblastoma (Rb), RARβ, and adenomatous polyposis coli (APC) gene promoters [37]. Presumably, downregulation of DNMT3b may partly potentiate the sensitivity of DU145 cells to ATRA, and this may establish a positive feedback between the ATRA treatment and the downregulation of DNMT3b to facilitate the HOXB13 expression, and consequently to induce the growth arrest of DU145 cells. In this study, we found that ATRA was able to upregulate the expression of HOXB13 and to induce DU145 cells growth arrest as a result of the reduced methylation level of HOXB13. This raises a question of whether a synergistic effect between ATRA and DNMT inhibitors, e.g., 5-aza-dC, exists. Results from our MTT and real-time PCR experiments supported this assumption, since simultaneous treatment of both ATRA and 5-aza-dC exhibited a much stronger inhibitory effect to DU145 cells than each of the two drugs alone (Fig. S6). Meanwhile, the expression of HOXB13 was upregulated, but both EZH2 and DNMT3b were downregulated markedly upon the treatment of the two drugs (Fig. S7).

Altogether, data presented in this report support a working model in which HOXB13, EZH2 and DNMT3b are involved in ATRA-induced cell growth arrest in DU145 cells (Fig. 6). Specifically, ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 promoter induced by EZH2 and DNMT3b. Perspectively, data arising from this study may provide useful clues for the development of new therapeutic strategies for AR prostate cancer that involve the use of ATRA and epigenetic modifiers.

Materials and Methods

Cell Culture and Reagents
DU145, PC-3, LNCap, 293 and 293T cells were purchased from the Institute of Cell Biology (Shanghai, China). Cells were maintained in F12 (DU145 and PC-3), 1640 (LNCap) and DMEM (293 and 293T) media (Gibco), respectively, supplemented with 10% FBS, 100 μg/ml penicillin and 100 μg/ml streptomycin in an humidified atmosphere containing 5% CO2 at 37°C. ATRA (Sigma, R2625-1G) was dissolved in absolute ethanol at 10–2 M, and stored at −20°C for in vitro studies. 5-aza-2-deoxycytidine (5-aza-dC, Sigma, A3656-5 mg) was dissolved in acetic acid at 10–2 M, and stored at −20°C for in vitro studies.

Transfection and Plasmid Constructs

Transient transfection of DU145 cells was performed using the FuGENE HD transfection (Roche) procedure. The plasmids for RNA interferring experiments were generated by inserting an oligonucleotide containing a specific siRNA targeting sequence into the pSilencer4.1-CMV-neo vector (Ambion Applied Biosystems, USA). The targeting sequences were: EZH2: 5’-cagcattgctggcaccatctg-3’ [45]; BMI1: 5’-gaccagcagctcaatttgctgttggaaccg-3’ [45]; DNMT3b: 5’-gaccagcagctcaatttgctgttggaaccg-3’ [46] and HOXB13: 5’-gaccagcagctcaatttgctgttggaaccg-3’ [10].

RT-PCR and Real-time PCR

RNA extraction and RT-PCR were performed as previously described [47]. Quantitative real-time RT-PCR was carried out on an ABI Prism7000 Sequence Detection System (Applied Biosystems), and SYBR Green (TOYOBO) was used as a double-stranded DNA-specific fluorescent dye. The PCR primer sequences were: EZH2, 5’-tctattgctggcaccatctg-3’ (sense), 5’-tctattgctggcaccatctg-3’ (antisense); BMI1, 5’-gaccagcagctcaatttgctgttggaaccg-3’ (sense), 5’-gaccagcagctcaatttgctgttggaaccg-3’ (antisense); BMI1, 5’-gaccagcagctcaatttgctgttggaaccg-3’ (sense), 5’-gaccagcagctcaatttgctgttggaaccg-3’ (antisense); BMI1, 5’-gaccagcagctcaatttgctgttggaaccg-3’ (sense), 5’-gaccagcagctcaatttgctgttggaaccg-3’ (antisense).
tisense); HOXB13, 5'-gagccggcacaagcaat-3' (sense), 5'-acagaggacagagacatacctgca-3' (antisense); and β-actin, 5'-ctgctggagacataggag-3' (sense), 5'-atgctagcgttatgggtctggt-3' (antisense).

Western Blot and Co-immunoprecipitation (CoIP)
Protein extraction and western blot analysis were performed in DU145 and LNCap cells as previously described [11]. β-actin was used as an internal control for normalizing the loading materials. Co-precipitation was performed in DU145 cells as described previously [48]. Total cell extracts were pre-cleared with 40 μl protein A-agarose at 4°C for 1 h. The supernatant was incubated with the anti-EZH2 or anti-DNMT3b with gentle shacking for 1 h at 4°C followed by addition of 40 μl of protein A-agarose for another 3 h. The beads were resuspended in 100 μl of 2×loading buffer and boiled for 10 min. The proteins prepared were immunoblotted with anti-DNMT3b or anti-EZH2 antibody.

Statistical Analysis
Statistical significance was set at 0.05 or 0.01 for all tests. Results are shown as means±S.D.

Supporting Information
Figure S1 ATRA induced PC-3 cell growth arrest in a dose-dependent fashion. PC-3 cells were treated with various concentrations of ATRA for 72 h and the proliferation rate was assessed by MTT assays. *P<0.05, **P<0.01 (n = 6).
(TIF)

Figure S2 ATRA affected the expressions of HOXB13, EZH2 and DNMT3b in PC-3 cell line. ATRA upregulated HOXB13 expression and reduced the expressions of EZH2 and DNMT3b at mRNA (A) and protein (B) levels in another prostate cancer cells, PC-3.
(TIF)

Figure S3 A time course of ATRA effect on the expressions of HOXB13, EZH2 and DNMT3b in DU145 cells. RT-PCR was used to test the changes of the expressions of HOXB13, EZH2 and DNMT3b at mRNA level in DU145 cells treated daily upon 80 μM ATRA.
(TIF)

Figure S4 The expression of HOXB13 in different malignancy prostate cancer cell lines, DU145 and LNCap. RT-PCR was used to assess the HOXB13 expression at mRNA level in DU145 and LNCap cells (A), and western blotting was used to determine the HOXB13 expression at protein level in DU145 and LNCap cells (B).
(TIF)

Figure S5 ATRA did not alter the expressions of HOXB13, EZH2 and DNMT3b at mRNA level in normal cells, 293 and 293T. ATRA induced growth arrest in 293 and 293T cells in a dose-dependent manner (A). 293 and 293T cells were treated with various concentrations of ATRA for 72 h and tested by MTT assays. *P<0.05, **P<0.01 (n = 6). RT-PCR was used to examine the expressions of HOXB13, EZH2 and DNMT3b at mRNA level in 293 and 293T cells treatment upon 40 μM ATRA for 3 days (B).
(TIF)

Figure S6 The anti-proliferative effect of the combined use of ATRA and 5-aza-dc in DU145 cells. Cytotoxicity was determined by the MTT assays in 72-hour cultures. Results are the means of six independent experiments. The error bars represent the standard deviations. The concentrations of the two drugs are both in μM. *P<0.05, **P<0.01 (n = 6).
(TIF)

Figure S7 Coordinate regulation of the expressions of HOXB13, EZH2 and DNMT3b by ATRA and 5-aza-dc in DU145 cells. The real-time PCR assessments of the expressions of HOXB13 (A), EZH2 (B) and DNMT3b (C) at mRNA level in DU145 cells treated with 5-aza-dc alone, ATRA alone or with a combination of both. *P<0.05, **P<0.01 (n = 3).
(TIF)

Author Contributions
Conceived and designed the experiments: ZWL GLR JL BQH. Performed the experiments: ZWL GLR CYSG LJG WNZ. Analyzed the data: ZWL GLR ZXJ YYL YZ XLW. Contributed reagents/materials/analysis tools: ZWL GLR LZ PFH. Wrote the paper: ZWL BQH. Designed the software used in analysis: ZWL. Obtained permission for use of cell line: ZWL, GLR JL BQH.
References

1. Schlemmer HP (2008) [Prostate carcinoma]. Radiologe 48: 45–51.
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
3. van Leenders GJ, Dukers D, Hessels D, van der Kieboom SW, Houbenaga CA, et al. (2007) Polycomb-group oncogenes EZH2, BMI1, and KRING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52: 453–463.
4. Kahlem P, Dorken B, Schmitt CA (2004) Cellular senescence in cancer treatment: friend or foe? J Clin Invest 113: 169–174.
5. Jung C, Kim RS, Lee SJ, Wang C, Jeng MH (2004a) HOXB13 homoeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res 64: 3046–3051.
6. Lewis MT (2000) Homeobox genes in mammary gland development and neoplasia. Breast Cancer Res 2: 158–169.
7. Kim YR, Oh KJ, Park SY, Kang TW, et al. (2010) HOXB13 homeobox gene is a negative regulator of p21/CDKN1A expression. Mol Cancer Res.
8. Economides KD, Capecchi MR (2003) Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 130: 2061–2069.
9. Mack JA, Li L, Sato N, Haccau VC, Maytin EV (2005) Hoxb13 up-regulates transglutaminase activity and drives terminal differentiation in an embryonic organotypic model. J Biol Chem 280: 29904–29911.
10. Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH (2004b) EZH2 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res 64: 9185–9192.
11. Ren G, Zhang G, Dong Z, Lin Z, Li L, et al. (2009) Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. Int J Biochem Cell Biol 41: 1094–1101.
12. Miyachi J (1999) All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. Leuk Lymphoma 33: 267–280.
13. Siddiquizaman, Guruvayoorappan C, Berlin Grace VM (2010) All Trans Retinoic Acid and Cancer. Immunopharmacol Immunotoxicol.
14. Drach J, Lopez-Berestein G, McQueen T, Andreff M, Meltz K (1995) Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 55: 2100–2104.
15. Hagwara Y, Kasukabe T, Kazezko Y, Nitura N, Okabe-Kado J (2010) Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells. Int J Hematol 93: 136–143.
16. Hoang TC, Bui TK, Takushi T, Watanabe T, Sato Y (2010) All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein. J Exp Clin Cancer Res 29: 165.
17. Zhang XQ (2002) Vitamin A and apoptosis in prostate cancer. Endocr Relat Cancer 9: 87–102.
18. Kuczekzebyk Y, Gul MK, Cengiz E, Erten C, Karaca B, et al. (2008) Enhancement of doxorubicin-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and AsPC1 pancreatic carcinoma cell lines. Cancer Lett 255: 153–159.
19. Fan T, Jiang S, Chung N, Alikhan A, Ni C, et al. (2011) EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res.
20. Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, et al. (2011) Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol.
21. Hoffmann MJ, Engers R, Florl AR, Ott AR, Muller M, et al. (2007) Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 6: 1403–1412.
22. Bruchle D, Strahl G, Muller J (2001) Polycomb group proteins and heritable silencing of Drosophila Hox genes. Development 128: 993–1004.
23. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cumcliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67: 547–556.
24. Du J, Li L, Ou Z, Kong C, Zhang Y, et al. (2011) FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res Treat.